NCT03902184 (TELLOMAK) is a Phase 2 clinical trial of IPH4102 in Lymphoma, T-Cell, sponsored by Innate Pharma.

Who is sponsoring NCT03902184?

NCT03902184 is sponsored by Innate Pharma.

What drugs are being tested in NCT03902184?

Interventions in NCT03902184: IPH4102.

What condition does NCT03902184 study?

NCT03902184 studies Lymphoma, T-Cell, Lymphoma, T-Cell, Cutaneous, Mycosis Fungoides/Sezary Syndrome.

Is NCT03902184 still recruiting?

NCT03902184 is currently active, enrolled. Last updated 8 November 2024.

Last reviewed 2024-11-08 · How we verify

NCT03902184: TELLOMAK

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

IPH4102 Alone or in Combination With Chemotherapy in Patients With Advanced T Cell Lymphoma

Active, enrolled Phase 2 Last updated 8 November 2024

What this trial tests

Phase 2 trial testing IPH4102 in Lymphoma, T-Cell in 170 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

22 May 2019

Primary endpoint
31 October 2023

31 January 2026

Quick facts

Lead sponsor	Innate Pharma
Phase	Phase 2
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	170
Start date	22 May 2019
Primary completion	31 October 2023
Estimated completion	31 January 2026
Sites	53 locations across France, Italy, Belgium, Austria, Germany, Poland, United States, Spain

Drugs / interventions tested

IPH4102 — full drug profile →

Conditions studied

Lymphoma, T-Cell — all drugs for Lymphoma, T-Cell →
Lymphoma, T-Cell, Cutaneous — all drugs for Lymphoma, T-Cell, Cutaneous →
Mycosis Fungoides/Sezary Syndrome — all drugs for Mycosis Fungoides/Sezary Syndrome →

Sponsor

Innate Pharma — full company profile →

Who can join

18 and older, any sex, with Lymphoma, T-Cell or Lymphoma, T-Cell, Cutaneous. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is an open label, multi-cohort, and multi-center phase II study, which evaluates the clinical activity and safety of IPH4102 in Sezary Syndrome and Mycosis fungoides as single agent.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

NK Cell-Based Immune Checkpoint Inhibition.
Khan M, Arooj S, Wang H. · · 2020 · cited 296× · PMID 32117298 · DOI 10.3389/fimmu.2020.00167
Exploiting innate immunity for cancer immunotherapy.
Yi M, Li T, Niu M, Mei Q, et al · · 2023 · cited 151× · PMID 38008741 · DOI 10.1186/s12943-023-01885-w
Natural killer cells: a promising immunotherapy for cancer.
Chu J, Gao F, Yan M, Zhao S, et al · · 2022 · cited 140× · PMID 35606854 · DOI 10.1186/s12967-022-03437-0
Advances in targeted therapy for malignant lymphoma.
Wang L, Qin W, Huo YJ, Li X, et al · · 2020 · cited 88× · PMID 32296035 · DOI 10.1038/s41392-020-0113-2
The Rise of NK Cell Checkpoints as Promising Therapeutic Targets in Cancer Immunotherapy.
Sun H, Sun C. · · 2019 · cited 88× · PMID 31681269 · DOI 10.3389/fimmu.2019.02354
Targeting NK Cell Checkpoint Receptors or Molecules for Cancer Immunotherapy.
Zhang C, Liu Y. · · 2020 · cited 75× · PMID 32714324 · DOI 10.3389/fimmu.2020.01295
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.
Archilla-Ortega A, Domuro C, Martin-Liberal J, Muñoz P. · · 2022 · cited 61× · PMID 35164813 · DOI 10.1186/s13046-022-02264-x
Novel targeted therapies of T cell lymphomas.
Iżykowska K, Rassek K, Korsak D, Przybylski GK, et al · · 2020 · cited 49× · PMID 33384022 · DOI 10.1186/s13045-020-01006-w

Verify or expand the search:

Other recruiting trials for Lymphoma, T-Cell

Currently open trials in the same condition.

NCT07356245 — Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma · Phase 2 · recruiting
NCT06716658 — JAK1 Inhibitor Golidocitnib for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas · Phase 2 · recruiting
NCT06530550 — PI3K Inhibitors for the Treatment of Relapsed/Refractory Indolent T/NK-cell Lymphomas · Phase 2 · recruiting
NCT05476770 — Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies · Phase 1 · recruiting
NCT04104776 — A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas · Phase 1, PHASE2 · recruiting

Other Innate Pharma trials

Trials by the same sponsor.

NCT06088654 — Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma · Phase 1, PHASE2 · terminated
NCT05321147 — Safety and Efficacy of Lacutamab in Patients With Relapsed/Refractory Peripheral T-cell Lymphoma That Express KIR3DL2 · Phase 1 · completed
NCT03665129 — IPH5401 (Anti-C5aR) in Combination With Durvalumab in Patients With Advanced Solid Tumors · Phase 1 · terminated
NCT02557516 — Combination Study of IPH2201 (Monalizumab) With Ibrutinib in Relapsed, Refractory or Previously Untreated CLL · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03902184 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Innate Pharma
Last refreshed: 8 November 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03902184.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing